Frontiers in Oncology (Dec 2017)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

  • David J. Sher

DOI
https://doi.org/10.3389/fonc.2017.00281
Journal volume & issue
Vol. 7

Abstract

Read online

The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadjuvant strategies have been developed to treat micrometastatic disease and increase the probability of a complete resection. The optimal induction strategy has not yet been defined, however, with arguments favoring either preoperative chemotherapy or CRT. In this article, the data supporting the use of neoadjuvant CRT and the randomized literature comparing the two approaches will be reviewed. The article will conclude with summary comparisons of these induction paradigms.

Keywords